Diabetes mellitus and pancreas cancer

Česká verzia

Authors: Jan Škrha ¹; Pavel Škrha ²; Přemysl Frič ³
Authors place of work: III. interní klinika 1. LF UK a VFN Praha ¹; II. interní klinika 3. LF UK a FN Královské Vinohrady, Praha ²; Interní klinika 1. LF UK a Ústřední vojenská nemocnice – Vojenská fakultní nemocnice, Praha ³
Published in the journal: Vnitř Lék 2016; 62(3): 202-209
Category: Reviews

Summary

Diabetes mellitus and pancreatic cancer establish both-side relationship, one disease may have influence a development of the other. Pathogenic mechanisms sharing their relationship are overviewed. Early diagnosis may contribute to better prognosis of the patients with malign tumor. The treatment by antidiabetic drugs offer to diabetic patients different risks of pancreatic cancer but lots of data are still lacking.

Key words:
antidiabetic drugs – diabetes mellitus – early diagnosis – pancreatic carcinoma – pathogenic mechanisms

Zdroje

1. Ben Q, Xu M, Ning X et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer 2011; 47(13): 1928–1937.

2. Li D, Tang H, Hassan M et al. Diabetes and risk of pancreatic cancer: a pooled analysis of three large case-control studies. Cancer Causes Control 2011; 22(2): 189–197.

3. Cui Y, Andersen DK. Diabetes and pancreatic cancer. Endocr Relat Cancer 2012; 19(5): F9-F26.

4. Frič P, Šedo A, Škrha J et al. Časná detekce sporadického karcinomu pankreatu. Čas Lék Čes 2016; 155(1): 44–47.

5. Ferlay E, Soerjomataman I, Dikshitc R et al. Cancer incidence and mortality world-wide: sources, methods and major patterns in Globocan 2012. Int J Cancer 2015; 136(5): E359-E386.

6. Mayer EJ, Newman B, Austin MA et al. Genetic and environmental influences on insulin levels and the insulin resistance syndrome: an analysis of women twins. Am J Epidemiol 1996; 143(4): 323–332.

7. Rebours V, Gaujoux S, d’Assignies G et al. Obesity and Fatty Pancreatic Infiltration Are Risk Factors for Pancreatic Precancerous Lesions (PanIN). Clin Canc Res 2015; 21(15): 3522–3528.

8. Wei L, Zhenhua M, Jiguang M et al. Hydrogen peroxide mediates hyperglycemia-induced invasive activity via ERK and p38 MAPK in human pancreatic cancer. Oncotarget 2015; 6(31): 31119–31133.

9. Arcidiacono B, Iiritano S, Nocera A et al. Insulin Resistance and Cancer Risk: An Overview of the Pathogenetic Mechanisms. Exp Diab Res 2012; 2012: 789174. Dostupné z DOI: http://dx.doi.org/10.1155/2012/789174.

10. Li JH, Ma JG, Han L et al. Hyperglycemic tumor microenvironment induces perineural invasion in pancreatic cancer. Canc Biol Ther 2015; 16(6): 912–921.

11. Pannala R, Leibson CL, Rabe KG et al. Temporal association of changes in fasting blood glucose and body mass index with diagnosis of pancreatic cancer. Am J Gastroenterol 2009; 104(9): 2318–2325.

12. Song S, Wang B, Zhang X et al. Long-Term Diabetes Mellitus Is Associated with an Increased Risk of Pancreatic Cancer: A Meta-Analysis. PLoS One 2015; 10(7): e0134321. Dostupné z DOI: http://dx.doi.org/doi:10.1371/journal.pone.0134321.

13. Batabyal P, Vander Hoorn S, Christophi Ch et al. Association of Diabetes Mellitus and Pancreatic Adenocarcinoma: A Meta-Analysis of 88 Studies. Ann Surg Oncol 2014; 21(7): 2453–2462.

14. Chari ST, Leibson CL, Rabe KG et al. Pancreatic cancer associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 2008; 134(1): 95–101.

15. Ben Q, Xu M, Ning X et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer 2011; 47(13): 1928–1937.

16. Sah RP, Nagpal SJ, Mukhopadhyay D et al. New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol 2013; 10(7): 423–433.

17. Permert J, Ihse I, Jorfeldt L et al. Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg 1993; 80(8):1047–1050.

18. Aggarwal G, Ramachandran V, Javeed N et al. Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in beta cells and mice. Gastroenterology 2012; 143(6): 1510–1517.

19. Javeed N, Sagar G, Dutta SK et al. Pancreatic cancer-derived exosomes cause paraneoplastic beta-cell dysfunction. Clin Canc Res 2015; 21(7): 1722–1733. Erratum in – Correction: Pancreatic Cancer-Derived Exosomes Causes Paraneoplastic β-cell Dysfunction. [Clin Cancer Res. 2015].

20. Frič P, Zavoral M. Early diagnosis of pancreatic adenocarcinoma. Role of stroma, surface proteases, and glucose-homeostatic agents. Pancreas 2012; 41(5): 663–670.

21. Bušek P, Vaníčková Z, Hrabal P et al. Increased tissue and circulating levels of dipeptidyl peptidase-IV enzymatic aktivity in patients with pancreatic ductal adenocarcinoma. Pancreatology 2016 (in press).

22. Teichenne J, Morro M, Casellas A et al. Identification of miRNAs involved in reprogramming acinar cells into insulin producing cells. PLoS One 2015; 10(12): e0145116. Dostupné z DOI: http://dx.doi.org/10.1371/journal.pone.0145116.

23. Filios SR, Shalev A. β-Cell MicroRNAs: Small but powerful. Diabetes 2015; 64(11): 3631–3644.

24. Krechler T, Zeman M, Vecka M et al. Leptin and adiponectin in pancreatic cancer connection with diabetes mellitus. Neoplasma 2011; 58(1): 58–64.

25. Dranka-Bojarowska D, Lekstani A, Olakowski M et al. The assessment of serum concentration of adiponectin, leptin and serum carbohydrate antigen-19.9 in patients with pancreatic cancer and chronic pancreatitis. J Physiol Pharmacol 2015; 66(5): 653–663.

26. Bauden M, Pamart D, Ansari D et al. Circulating nucleosomes as epigenetic biomarkers in pancreatic cancer. Clin Epigenet 2015; 7: 106. Dostupné z DOI: http://dx.doi.org/10.1186/s13148–015–0139–4.

27. Škrha P, Hořínek A, Anděl M et al. miRNA-192, miRNA-21 a miRNA-200: nové marker karcinomu pankreatu u diabetiků? Vnitř Lék 2015; 61(4): 351–354.

28. Le Large TYS, Meijer LL, Prado MM et al. Circulating microRNAs as diagnostic biomarkers for pancreatic cancer. Exp Rev Molec Diagn 2015; 15(12): 1525–1529.

29. Visani M, Acquaviva G, Fiorino S et al. Contribution of microRNA analysis to characterisation of pancreatic lesions: a review. J Clin Pathol 2015; 68(11): 859–869.

30. Tokajuk A, Krzyzanowska-Grycel E, Tokajuk A et al. Antidiabetic drugs and risk of cancer. Pharmacol Rep 2015; 67(6): 1240–1250.

31. Tang X, Yang L, He ZY et al. Insulin Glargine and Cancer Risk in Patients with Diabetes: A Meta-Analysis. PLoS One 2012; 7: e51814. Dostupné z DOI: http://dx.doi.org/10.1371/journal.pone.0051814.

32. Gerstein HC, Bosch J, Dagenais GR et al. (ORIGIN Trial Investigators). Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319–328.

33. van Staa TP, Patel D, Gallagher AM et al. Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. Diabetologia 2012; 55(3): 654–665.

34. Bodmer M, Becker C, Meier C et al. Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. Am J Gastroenterol 2012; 107(4): 620–626.

35. Singh S, Singh PP, Singh AP et al. Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: A systemic review and metaanalysis. Am J Gastroenterol 2013; 108(4): 510–519; quiz 520. Dostupné z DOI: http://dx.doi.org/10.1038/ajg.2013.7.

36. Hsieh MC, Lee TC, Cheng SM et al. The influence of Typ 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diab Res 2012; 2012: 413782. Dostupné z DOI: http://dx.doi.org/10.1155/2012/413782.

37. Kato K, Iwama H, Yamashita T et al. The antidiabetic drug metformin inhibits pancreatic cancer cell proliferation in vitro and in vivo. Study of the microRNAs associated with the antitumor effect of metformin. Oncol Rep 2016; 35(3): 1582–1592.

38. Cheng G, Lanza-Jacoby S. Metformin decreases growth of pancreatic cancer cells by decreasing reactive oxygen species: Role of NOX4. Biochem Biophys Res Commun 2015; 465(1): 41–46.

39. Chai XQ, Chu HP, Yang X et al. Metformin Increases Sensitivity of Pancreatic Cancer Cells to Gemcitabine by Reducing CD133(+) Cell Populations and Suppressing ERK/P70S6K Signaling. Sci Rep 2015; 5:14404. Dostupné z DOI: http://dx.doi.org/10.1038/srep14404.

40. Kordes S, Pollak MN, Zwinderman AH et al. Metformin in patients with advanced pancreatic cancer: a double-blind, randomized, placebo-controlled phase 2 trial. LANCET Oncol 2015; 16(7): 839–847.

41. Choi Y, Kim TY, Oh DY et al. The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy. Canc Res Treat 2016; 48(1): 171–179.

42. Okumura T. Mechanisms by which thiazolidinediones induce anticancer effects in cancers in digestive organs. J Gastroenterol 2010; 45(11): 1097–1102.

43. Ninomiya I, Yamazaki K, Oyama K et al. Pioglitazone inhibits the proliferation and metastasis of human pancreatic cancer cells. Oncol Lett 2014; 8(6): 2709–2714.

44. Sawai H, Liu J, Reber HA et al. Activation of peroxisome proliferator-activated receptor-gamma decreases pancreatic cancer cell invasion through modulation of the plasminogen activator system. Mol Cancer Res 2006; 4(3): 159–167.

45. Li D, Yeung SC, Hassan MM et al. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009; 137(2): 482–488.

46. Zhao H, Wang L, Wei R et al. Activation of glucagon-like peptide-1 receptor inhibits tumorigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway. Diab Obes Metab 2014; 16(9): 850–860.

47. Knapen LM, van Dalem J, Keulemans YC et al. Use of incretin agents and risk of pancreatic cancer: a population-based cohort study. Diab Obes Metab 2016; 18(3): 258–265.

48. Tseng CH, Lee KY, Tseng FH. An updated review on cancer risk associated with incretin mimetics and enhancers. J Environment Sci Health 2015; 33(1): 67–124.

49. Gokhale M, Buse JB, Gray CL et al. Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study. Diab Obes Metab 2014; 16(12): 1247–1256.

50. Nagel AK, Ahmed-Sarwar N, Werner PM et al. Dipeptidyl peptidase-4 inhibitor-associated pancreaticcarcinoma: A review of the FAERS database. Ann Pharmacother 2016; 50(1): 27–31.

51. Tseng CH. Sitagliptin and pancreatic cancer risk in patients with type 2 diabetes. Eur J Clin Invest 2016; 46(1): 70–79.

52. Scafoglio C, Hirayama BA, Kepe V et al. Functional expression of sodium-glucose transporters in cancer. Proc Nat Acad Sci USA 2015; 112(30): E4111-E4119. Dostupné z DOI: http://dx.doi.org/10.1073/pnas.1511698112.

53. Tseng CH. Thyroid cancer risk is not increased in diabetic patients. PLoS One 2012; 7(12): e53096. Dostupné z DOI: http://dx.doi.org/10.1371/journal.pone.0053096.

54. Tseng YH, Tsan YT, Chan WC et al. Use of an α-glucosidase inhibitor and the risk of colorectal cancer in patients with diabetes: A nationwide, population-based cohort study. Diabetes Care 2015; 38(11): 2068–2074.